DSIP (Delta Sleep-Inducing Peptide)
Nonapeptide first isolated from rabbit brain during induced sleep (emideltide); not approved; small human studies from the 1980s-1990s; FDA compounding-risk list: immunogenicity, no safety information for the proposed route.
60-Second Scientific Briefing
DSIP (delta sleep-inducing peptide, emideltide) is a nine-amino-acid peptide first described in the 1970s for its link with deep sleep. It is not approved as a medicine anywhere. Human research is limited to small studies from the 1980s and 1990s; controlled studies in healthy volunteers found no effect on stimulated ACTH and cortisol or on growth hormone and prolactin. The FDA cites a risk of immunogenicity and no safety information for its proposed routes.
What is DSIP (Delta Sleep-Inducing Peptide)?
Pharmacological Classification & Molecular IdentityDSIP (emideltide) is a nine-amino-acid peptide described in the 1970s in connection with deep (delta) sleep. It has also been described as a possible inhibitor of pituitary ACTH release. [1] Psychoneuroendocrinology, 1995 ↗
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingReceptor Selectivity: No specific receptor has been established. Human studies tested whether it changes pituitary hormones: one study in 8 men reported a fall in ACTH without a change in vasopressin, while another in healthy men found no effect on CRH-stimulated or meal-related ACTH and cortisol. [1] Psychoneuroendocrinology, 1995 ↗ [2] Horm Res, 1994 ↗
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA or any other regulator. In its 2026 compounding-risk list the FDA cites a risk of immunogenicity and no safety information for the proposed route of administration for emideltide (DSIP). [1] U.S. Food and Drug Administration, 2026 ↗
DSIP (Delta Sleep-Inducing Peptide) is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesHuman data are small and old. Placebo-controlled endocrine studies in healthy volunteers: no effect on CRH-stimulated or meal-related ACTH and cortisol (20 men, 1995); no effect on spontaneous or arginine-stimulated growth hormone and prolactin (8 women, 1993); a decrease in ACTH without a change in vasopressin (15 men, 1994). Sleep studies in insomnia were published in the 1980s (for example Eur Neurol 1984) without modern trial standards. No large or recent randomised trial has been published. [1] Psychoneuroendocrinology, 1995 ↗ [2] Horm Res, 1994 ↗ [3] Psychoneuroendocrinology, 1993 ↗ [4] Eur Neurol, 1984 ↗
Clinical Evidence
Human data are small and old. Placebo-controlled endocrine studies in healthy volunteers: no effect on CRH-stimulated or meal-related ACTH and cortisol (20 men, 1995); no effect on spontaneous or arginine-stimulated growth hormone and prolactin (8 women, 1993); a decrease in ACTH without a change in vasopressin (15 men, 1994). Sleep studies in insomnia were published in the 1980s (for example Eur Neurol 1984) without modern trial standards. No large or recent randomised trial has been published.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesThere is no clinical safety dataset. The FDA cites a risk of immunogenicity and no safety information for the proposed route of administration. [1] U.S. Food and Drug Administration, 2026 ↗
Its receptor, mechanism, efficacy for sleep, long-term safety and the quality of non-pharmaceutical material are unknown. [1] U.S. Food and Drug Administration, 2026 ↗
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNo dose is approved or established. The amounts used in the published studies are part of each study's design and are described in the linked papers; they are not a recommendation. [1] U.S. Food and Drug Administration, 2026 ↗
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- DSIP (emideltide) is a nine-amino-acid peptide described in the 1970s in connection with deep (delta) sleep. It has also been described as a possible inhibitor of pituitary ACTH release.
- Targets & Selectivity: No specific receptor has been established. Human studies tested whether it changes pituitary hormones: one study in 8 men reported a fall in ACTH without a change in vasopressin, while another in healthy men found no effect on CRH-stimulated or meal-related ACTH and cortisol.
- Human data are small and old. Placebo-controlled endocrine studies in healthy volunteers: no effect on CRH-stimulated or meal-related ACTH and cortisol (20 men, 1995); no effect on spontaneous or arginine-stimulated growth hormone and prolactin (8 women, 1993); a decrease in ACTH without a change in vasopressin (15 men, 1994). Sleep studies in insomnia were published in the 1980s (for example Eur Neurol 1984) without modern trial standards. No large or recent randomised trial has been published.
- Safety considerations: There is no clinical safety dataset. The FDA cites a risk of immunogenicity and no safety information for the proposed route of administration.
? Unknown / Under Ongoing Investigation
- Its receptor, mechanism, efficacy for sleep, long-term safety and the quality of non-pharmaceutical material are unknown.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysDSIP (emideltide) is a nine-amino-acid peptide described in the 1970s in connection with deep sleep. It is a research compound and is not approved as a medicine.
- Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion (Psychoneuroendocrinology, 1995-01-01)
- Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women (Psychoneuroendocrinology, 1993-01-01)
No specific receptor has been established. Human studies on pituitary hormones were inconsistent: one reported lower ACTH, another found no effect on ACTH and cortisol.
- Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion (Psychoneuroendocrinology, 1995-01-01)
- Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men (Horm Res, 1994-01-01)
No. DSIP is not approved anywhere. The FDA cites a risk of immunogenicity and no safety information for its proposed route.
- Certain bulk drug substances for use in compounding that may present significant safety risks (U.S. Food and Drug Administration, 2026-04-22)
Only small studies from the 1980s and 1990s. Controlled studies in healthy volunteers found no effect on stimulated ACTH and cortisol or on growth hormone and prolactin. No large or recent randomised trial exists.
Psychoneuroendocrinology 1995: in healthy men, intravenous DSIP vs placebo did not change ACTH and cortisol responses to CRH (5 men per condition) or the meal-related midday ACTH and cortisol surge (10 men); the authors concluded their data do not support an inhibitory role on ACTH in humans. Psychoneuroendocrinology 1993: in 8 healthy women, DSIP did not change spontaneous or arginine-stimulated growth hormone and prolactin, or their daily rhythm. Horm Res 1994: in healthy men, DSIP lowered ACTH but did not change vasopressin at rest or after osmotic or postural stimulation. Insomnia studies were published in the 1980s (Eur Neurol 1984) without modern randomised-trial standards.
- Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion (Psychoneuroendocrinology, 1995-01-01)
- Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men (Horm Res, 1994-01-01)
- Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women (Psychoneuroendocrinology, 1993-01-01)
- DSIP in insomnia (Eur Neurol, 1984-01-01)
There is no clinical safety dataset. The FDA cites a risk of immunogenicity and no safety information for the proposed route.
- Certain bulk drug substances for use in compounding that may present significant safety risks (U.S. Food and Drug Administration, 2026-04-22)
What are the critical unknown safety aspects and clinical limitations of DSIP (Delta Sleep-Inducing Peptide)?
§Its receptor, mechanism, effect on sleep, long-term safety and the quality of non-pharmaceutical material are unknown.
- Certain bulk drug substances for use in compounding that may present significant safety risks (U.S. Food and Drug Administration, 2026-04-22)
No dose is approved or established. The amounts used in the published studies are part of each study's design and are described in the linked papers; they are not a recommendation.
- Certain bulk drug substances for use in compounding that may present significant safety risks (U.S. Food and Drug Administration, 2026-04-22)
There is no approved product label, so no official storage instructions exist.
It is not named individually on the 2026 WADA Prohibited List. Under section S0 (non-approved substances), any pharmacological substance without a current approval by a government health authority for human therapeutic use is prohibited at all times. Athletes should confirm with their national anti-doping organisation.
- WADA Prohibited List (World Anti-Doping Agency)
What is Egypt Peptides' official medical policy regarding DSIP (Delta Sleep-Inducing Peptide)?
§Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.
- Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion (Psychoneuroendocrinology, 1995-01-01)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and published studiesCertain bulk drug substances for use in compounding that may present significant safety risks ↗
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion ↗
https://pubmed.ncbi.nlm.nih.gov/7777652/
Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men ↗
https://pubmed.ncbi.nlm.nih.gov/7698722/
Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women ↗
https://pubmed.ncbi.nlm.nih.gov/8475226/
DSIP in insomnia ↗
https://pubmed.ncbi.nlm.nih.gov/6391925/